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ABSTRACT
Objective: We sought to compare the cost-effectiveness of different inter-
ventions that have been shown to improve adherence with antihyperten-
sive and lipid-lowering therapy, by combining a burden of nonadherence
model framework with literature-based data on adherence-improving
interventions.
Methods: MEDLINE was reviewed for studies that evaluated 1 adher-
ence intervention compared with a control, used an adherence measure
other than self-report, and followed patients for 6 months. Effectiveness
was assessed as Relative Improvement, ratio of adherence with an inter-
vention versus control. Costs, standardized to 12 months and adjusted to
2007 US$, and effectiveness estimates for each intervention were entered
into a previously published model designed to measure the burden of
nonadherence with antihypertensive and lipid-lowering medications, in a
hypertensive population. Outputs included direct medical costs and incre-
mental costs per quality-adjusted life-year (QALY) gained.
Results: After screening, 23 eligible adherence-improving interventions
were identiﬁed from 18 studies. Relative Improvement ranged from 1.13
to 3.60. After eliminating more costly/less effective interventions, two
remained. Self-monitoring, reminders, and educational materials incurred
total health-care costs of $17,520, and compared with no adherence
intervention, had an incremental cost-effectiveness ratio (ICER) of $4984
per QALY gained. Pharmacist/nurse management incurred total health-
care costs of $17,896, and versus self-monitoring, reminders, and educa-
tion had an ICER of $6358 per QALY gained.
Conclusions: Of published interventions shown to improve adherence,
reminders and educational materials, and a pharmacist/nurse management
program, appear to be cost-effective and should be considered before other
interventions. Understanding relative cost-effectiveness of adherence inter-
ventions may guide design and implementation of efﬁcient adherence-
improving programs
Keywords: improving adherence, cost-effectiveness, literature review,
adherence intervention, antihypertensive, lipid-lowering, cardiovascular
disease.
Introduction
The efﬁcacy of recommended treatment regimens depends on
how well patients adhere to them. Accordingly, improving adher-
ence with medications that manage risk factors of cardiovascular
disease (CVD) has been shown to reduce cardiovascular events,
including the risk of recurrent myocardial infarction (MI) and
stroke, rehospitalizations, and all-cause mortality [1–4]. Improv-
ing adherence with medications is a key initiative of the World
Health Organization [5], and similar organizations worldwide.
Various strategies for improving adherence with medication
regimens, including medications for CVD, are available. These
include intensive case management by a pharmacist and/or
nurses [6–10]; patient education or counseling [11–13]; modiﬁ-
cations to dosing regimens or modiﬁcations to medication pack-
aging [14]; reminders for medications [14,15]; other
interventions, including home blood pressure (BP) monitoring to
improve adherence to hypertension medications [16]; and com-
binations of these approaches [15,17–19]. Nevertheless, different
types of intervention are seldom compared in one study and
overall costs of interventions are rarely captured.
A previous study using a comparative measure of “Relative
Improvement” demonstrated that the most successful adherence
interventions were personalized and intensive, typically including
management and counseling by health-care professionals, such as
a pharmacist or nurse [20]. Relative Improvement was calculated
as the ratio of effectiveness with the intervention versus the
control group, and enabled comparison across a diverse range of
studies [20]. To further facilitate comparison among studies,
costs were also estimated for each intervention. The authors
found that personalized and intensive interventions that were
most successful for improving adherence also tended to incur
higher costs than other, less successful interventions such as
reminders or changes to packaging [20].
To the best of our knowledge, a formal comparative cost-
effectiveness analysis across interventions designed to improve
adherence with CVD medications has not been undertaken. We
therefore decided to utilize a previously developed model that
analyzes the burden of nonadherence with antihypertensive and
lipid-lowering therapy under different levels of adherence, to
compare and contrast the cost-effectiveness of published adher-
ence interventions [21]. This model, used to predict relative
cost-effectiveness, permits modeling of real-world patient-care
settings, where adherence and persistence often fall short of the
“ideal” adherence seen in clinical trials [22,23]. A cost-effective
adherence intervention would be a method that is effective for
reducing the burden of illness associated with nonadherence, at
an optimal level of resource use. Accordingly, it is important to
consider the relative cost-effectiveness of adherence interven-
tions, particularly for determining applicability within health-
care environments in which resources are scarce.
We therefore sought to combine studies reporting a clear
improvement in adherence through application of each
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adherence intervention into a burden of nonadherence frame-
work [21], providing a comparative analysis of cost-effectiveness
across different intervention types from a payer’s perspective.
Methods
Study Identiﬁcation and Data Extraction
A prior review of MEDLINE publications by Petrilla et al. [24],
was extended to cover published articles (1972–2007) designed
to improve adherence with antihypertensive and/or lipid-
lowering medications. In short, eligible studies evaluated 1
adherence intervention compared with a control; used an adher-
ence measure other than self-report; and followed patients for
6 months. Interventions were excluded if they did not demon-
strate signiﬁcant improvement in adherence, as interventions that
reported negative or neutral outcomes would not have provided
a positive measure of Relative Improvement suitable for
comparison.
After screening 755 studies, ﬁve studies that described ﬁve
interventions were identiﬁed. In addition to the 18 interventions
previously identiﬁed [24]; this gave a total of 23 interventions
identiﬁed from 18 studies (Fig. 1). This information is detailed in
full in a separate publication [20].
Classiﬁcation and Effectiveness of
Adherence Interventions
From the studies identiﬁed, adherence-improving interventions
were broadly classiﬁed into those that involved an active input
from a health-care professional—physician, pharmacist,
nurse—to improve adherence for the patient (case management
[M]), those which involved education of the patient on the pre-
scribed product (reminders being sent [R] or education [E]),
other methods of intervention (O), or a combination of these
approaches (C) [20]. Combined approaches were classiﬁed
according to the primary method of intervention (e.g., C+R).
Effectiveness was assessed using Relative Improvement, deﬁned
as adherence outcome reported in the intervention group divided
by the adherence outcome reported in the control group.
Cost-Effectiveness Assessment
A “league table” listing all standardized interventions was used
to identify interventions that were eligible for cost-effectiveness
analysis. Steps in the league table comparison were: ﬁrst, all
interventions were ranked in ascending order of annualized cost;
second, identical interventions applied to more than one setting
or population were amalgamated into one intervention (average
of costs and average of effects); and third, interventions that were
more costly than interventions with higher efﬁcacy were consid-
ered dominated (less effective and more costly). One study by
McKenney et al. [7], used a 90% adherence threshold, rather
than the commonly used and accepted threshold of 80%
[2,4,22]. Furthermore, as McKenney et al. [7], did not provide
enough information on adherence outside of this threshold to
permit any inferences or calculations to standardize this study for
inclusion, the study was excluded from further analysis. All
nondominated interventions were entered into the cost-
effectiveness model for calculation of relative cost-effectiveness.
An informal panel process was used to estimate resource use
and costs for each intervention [20]. Studies were compared to
identify a set of common inputs from which comparable costs
could be inferred. Fixed costs at the site level, such as the cost of
training staff for the intervention, were not included, because the
average cost per patient would vary depending on scale. Drug
costs were included when we looked at the entire analysis but the
costs of the interventions themselves were initially determined
without any drug costs [21]. “No intervention” represents adher-
ence to calcium channel blocker (CCB) and lipid-lowering thera-
pies without any adherence-improving intervention.
Costs and effectiveness, from a payer’s perspective, for each
nondominated intervention were entered into the burden of non-
adherence model framework [21]. Costs were standardized to 12
months and adjusted to 2007 US$ using the medical care services
component of the Consumer Price Index [25].
Burden of Nonadherence Modeling
Patient characteristics were modeled based on the population
from the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid
Lowering Arm (ASCOT-LLA) [26], namely hypertensive patients
aged 40 to 79 years with total cholesterol6.5 mmol/L (241 mg/
dl) and 3 cardiovascular risk factors in addition to hyperten-
sion, including male sex, aged 55 years, stroke or transient
ischemic attack, type 2 diabetes mellitus, left ventricular hyper-
trophy, abnormal electrocardiogram, peripheral vascular disease,
Figure 1 Search strategy for identifying interventions designed to improve
adherence to antihypertensive and/or lipid-lowering therapy.
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microalbuminuria, or proteinuria [26]. The studies describing
adherence-improving interventions enrolled a variety of differing
patient groups (e.g., some enrolled new starters; some enrolled
previously nonadherent patients). Adjustments were not made
for differences between the patient populations included in each
of the adherence-improving intervention studies identiﬁed
and the ASCOT-LLA population. The assumption was made that
the patient population would not affect the outcome of the
intervention.
Lifetime costs, morbidity, and mortality associated with
adherence improvements from each intervention were estimated
over a lifetime horizon using a Monte Carlo microsimulation
model [21]. This model was constructed to compare costs and
outcomes of primary and secondary prevention with antihyper-
tensive and lipid-lowering medications under three adherence
scenarios: no treatment, ideal adherence, and real-world adher-
ence [21].
Brieﬂy, the no treatment model projected the natural history
of coronary heart disease and stroke in the absence of treatment
and formed the foundation for the other scenarios. Patients in
this model were taking neither antihypertensives nor lipid-
lowering therapy. Event frequencies and costs were assumed to
follow those found with nonadherent patients. The ideal adher-
ence scenario extended the no treatment scenario by adding
antihypertensive and lipid-lowering therapy and the associated
relative event risk reductions and costs. The real-world adher-
ence scenario was similar to the ideal adherence scenario but
added real-world adherence data and costs and beneﬁts associ-
ated with different level of adherence [21].
Adherence was assessed using proportion of days covered
(PDC), calculated as number of days with drug on-hand
divided by the number of days in the given time interval.
PDC has the advantage of simultaneously reﬂecting both com-
pliance and persistence [27,28] and provides a measure of
overall medication exposure compatible with the 1-year health
states in the model. PDC is also a commonly used parameter in
adherence studies [2,4,29–32], and its use therefore facilitates
meaningful comparisons across studies. For each therapy
(antihypertensive and lipid-lowering), three possible levels of
adherence were deﬁned, patients were allowed to transition
among them over time: fully adherent (PDC  80%); partially
adherent (PDC 21%–79%); and nonadherent (PDC 0–20%)
[21].
The Relative Improvement from each intervention study
identiﬁed was applied to patients’ baseline adherence in
the model, and the improved adherence was used to assign
adherence states based on their estimated adherence with
antihypertensive and lipid-lowering therapies (e.g., Full
[antihypertensive]–Full [lipid-lowering]; Full–Partial; Full–Non;
Partial–Full; Partial–Partial; Partial–Non; Non–Full; Non–
Partial; Non–Non).
Adherence distributions were modeled for each study. Ideal
adherence was based on adherence and effectiveness observed in
ASCOT-LLA [26]. Real-world adherence status was assigned at
the start of each model cycle according to real-world transitions.
Initial adherence status and transitions were drawn from pre-
scription claims data from California Medicaid (Medi-Cal) data
[33]. Nonadherent patients experienced the same cardiovascular
event rates as untreated patients, although fully adherent patients
receiving either treatment had a relative risk reduction applied
based on the ASCOT-LLA [26] data for patients treated with the
CCB, amlodipine besylate, and lipid-lowering agent, atorvastatin
calcium. The cardiovascular event rates for partially adherent
patients were estimated based on an arbitrary assumption of
50% efﬁcacy.
Annual Adherence Transitions
Adherence status transition probability matrices were made for
each year’s transition. Adherence transitions for year 1 were
based on the Relative Improvement from each adherence inter-
vention as applied to the ASCOT-LLA population’s baseline
adherence. Transitions beyond the ﬁrst year were based on exist-
ing annual adherence status transition probabilities in the model,
which were derived from ﬁlled prescription records from Medi-
Cal data [33]. Therefore, the beneﬁts of the adherence interven-
tions were captured in the ﬁrst year of treatment, although
adherence levels for patients beyond year 1 were based on long-
term adherence patterns seen in a representative population.
Statistical Analyses
Simulations of 200 trials of 5000 patients were conducted; means
of the 200 trials for each interventionwere reported.Outputswere
calculated on a per-person basis: costs (discounted) (angina, MI,
stroke, pharmacy, total); events (discounted) (angina, MI, stroke,
total); life-years (discounted); and quality-adjusted life-years
(QALYs) (discounted). The model employed a payer perspective,
including direct pharmacy and medical costs in 2007 $US with
future costs and beneﬁts discounted by 3% annually [34]. The
models were constructed and analyzed using TreeAge Pro 2006
(TreeAge Software Inc., Williamstown, MA). One-way sensitivity
analyses were conducted by varying our assumptions around the
percentage of therapeutic effectiveness patients receive when they
are partially adherent (PDC between 20% and 80%), and the
proportion of patients who are assumed to start out fully adherent
(PDC 80%) for both antihypertensive and lipid-lowering medi-
cations. Values for many of the modeled intervention variables
were not reported in the reviewed literature, making it difﬁcult to
specify plausible ranges; therefore, multiway and probabilistic
sensitivity analyses were not performed.
Results
Eligible Studies
After the league table comparison of 23 interventions from 18
studies identiﬁed from the literature analysis [20], ﬁve interven-
tions were eligible for analysis (Fig. 1): 1) mailed reminders (Skaer
et al. [14]); 2) combination intervention with self-monitoring,
reminders, and educational materials (Saunders et al. [19]); 3)
telephone counseling (Faulkner et al. [11]); 4) pharmacy and
nurse management (Bond and Monson [6]); and 5) pharmacist
management in an ambulatory setting (Monson et al. [10]).
Adherence distributions were modeled for the base-case (no
adherence) and each of the ﬁve studies (Table 1). For the base-
case of no adherence intervention, only 25% of patients were
estimated to be fully adherent with both CCB and lipid-lowering
therapies (Table 1). In contrast, 48% (Saunders et al. [19]) to
89% (Monson et al. [10]) of patients in the intervention groups
were estimated to be fully adherent with both therapies.
Effectiveness of Adherence-Improving Intervention
The Relative Improvement in adherence ranged from 1.13 for
mailed reminders [14] to 3.60 for a pharmacist management
program in an ambulatory setting [10] (Fig. 2). Annualized inter-
vention costs ranged from $19.18 per patient for mailed prescrip-
tion reminders [14] to $ 259.56 per patient for a pharmacists
management program in an ambulatory setting [10]. A combi-
nation program involving self-monitoring, reminders, and edu-
cational materials [19] was $25.46 more costly per patient than
reminders alone [14]. Pharmacist management in an ambulatory
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setting, where the pharmacist had sole responsibility for manag-
ing and educating patients [10], was $79.76 more expensive per
patient than a combined pharmacist and nurse management
program of compliance [6].
Cost-Effectiveness of Adherence-Improving Interventions
Modeled total cardiovascular events were highest for the group
receiving no adherence intervention (0.575), as would be
expected, and lowest for a pharmacist management program in
the ambulatory setting [10] (0.557) (Table 2). MI contributed the
highest event rate (0.222 to 0.230), followed by stroke (0.206 to
0.210), and angina (0.130 to 0.135). Predicted age of death was
highest (80.8 years) for the management programs [6,10] in
comparison with the other interventions for improving adher-
ence [11,14,19].
Simulated overall costs ranged from $18,082 for pharmacist
management program in the ambulatory setting [10] to $17,325
(no adherence intervention) (Table 3). Prescription costs were the
highest contributor to overall costs for each intervention and
ranged from $7990 for pharmacist management program in the
ambulatory setting [10] to $6982 (no adherence intervention).
Cardiovascular event costs (angina, MI, stroke) were lower with
any adherence-improving intervention than for no intervention.
After eliminating less effective/more costly interventions, two
interventions remained: self-monitoring, reminders, and educa-
tional materials (Saunders et al. [19]); and a pharmacist/nurse
Table 1 Initial adherence distributions for selected adherence-improving interventions
Adherence state
(antihypertensive–statin)
Adherence distribution
No adherence
intervention*
Skaer [14]
(R)
Saunders [19]
(C+R)
Faulkner [11]
(E)
Bond [6]
(M)
Monson [10]
(M)
Full–Full 0.246 0.447 0.482 0.525 0.779 0.887
Full–Partial 0.165 0.121 0.114 0.104 0.049 0.025
Full–Non 0.030 0.022 0.020 0.019 0.009 0.004
Partial–Full 0.095 0.070 0.065 0.060 0.028 0.014
Partial–Partial 0.228 0.167 0.157 0.144 0.067 0.034
Partial–Non 0.047 0.034 0.032 0.030 0.014 0.007
Non–Full 0.078 0.057 0.054 0.049 0.023 0.012
Non–Partial 0.072 0.053 0.049 0.045 0.021 0.011
Non–Non 0.039 0.029 0.027 0.025 0.011 0.006
*No adherence intervention = calcium channel blocker + statin only.
C+R, Combination + reminders; E, Education; M, Case management; R, Reminders.
Figure 2 Costs versus Relative Improvement in adherence, by type of intervention. *Relative Improvement = adherence outcome reported in the intervention group
divided by the adherence outcome reported in the control group. C+R, Combination + reminders; E, Education; M, Case management; R, Reminders.
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management program (Bond and Monson [6]) (Table 4).
(Monson [10] was an extension of the Bond and Monson [6]
intervention, and was dominated for cost per life-year gained.)
Compared with no adherence intervention, an intervention
involving self-monitoring, reminders, and educational materials
[19] had an ICER of $4984 per QALY gained, of $22,406 per
cardiovascular event avoided, and of $3642 per life-year gained.
The ICERs for a pharmacist/nurse management program [6]
versus self-monitoring, reminders, and educational materials [19]
were $6358 per QALY gained, $54,766 per cardiovascular event
avoided, and $4973 per life-year gained.
Sensitivity Analyses
Our base-case analysis assumed that patients who were partially
adherent (PDC between 21% and 79%) received 50% of the
therapeutic effectiveness that would be obtained by a fully adher-
ent patient. (Nonadherent patients, with PDC from 0% to 20%,
were assumed to get no therapeutic effect.) In a one-way sensi-
tivity analysis, this assumption was varied to assume 0%, 25%,
75%, and 100% of therapeutic effectiveness for the partially
adherent patients. The results of these analyses are shown in
Figure 3. As expected, QALYs gained increase, and costs
decrease, as partial effectiveness increases. These increases were
not linear however, as small variations in cost and effectiveness
changed the rank-ordering of the adherence interventions. In
general, the combination intervention with self-monitoring,
reminders, and educational materials (Saunders et al. [19]), phar-
macy and nurse management (Bond and Monson [6]), and phar-
macist management in an ambulatory setting (Monson et al.
[10]) remained relatively cost-effective.
A second set of sensitivity analyses was performed on the
initial percentage of patients that were considered fully adherent
to both medication types (antihypertensive and lipid-lowering).
That proportion depends on assumptions about the correlation
between rates of adherence to each medication type. If that
correlation is higher, more patients will be adherent to both; if
lower, we would expect fewer patients adherent to both (i.e.,
more patients adherent to one but not the other). To test the
sensitivity of our results, the proportion of patients who were
initially fully adherent was varied by 25%. Results were not
sensitive to 25% greater full adherence, with the same cost-
effectiveness rankings as in the base-case (Table 4). Nevertheless,
when 25% fewer patients were assumed to be fully adherent,
only the intervention involving reminders alone (Skaer et al. [14])
and pharmacist management in an ambulatory setting (Monson
et al. [10]) were found to be cost-effective.
Discussion
Despite an increased interest in improving adherence to therapies
for CVD [5], there are relatively few controlled studies evaluating
intervention strategies designed to improve adherence, and fewer
still include a cost-effectiveness assessment. Also, the overall
costs associated with these strategies for improving adherence
with medications for CVD may vary widely, raising the question
of which adherence intervention will provide the greatest beneﬁt
for the resources expended, and make the most economic sense
to recommend for a health care environment.
In this study, we were able to successfully combine data from
published interventions that improve adherence with antihyper-
tensive and lipid-lowering agents into a burden of nonadherence
framework [21]. By incorporating differences in adherence levels
within the model, we were able to assess how these different
adherence interventions would theoretically perform under a
real-world patient care setting.
Among the published adherence interventions evaluated, a
combination program involving self-monitoring, reminders, and
educational materials [19] and a pharmacist/nurse management
program [6] were estimated to be the most cost-effective methods
of improving adherence with antihypertensive and lipid-lowering
therapy in a real-world patient care setting. An intervention
involving reminders alone [14] incurred the lowest per-patient
costs, but was dominated by a combination program (i.e., pro-
vided less beneﬁt for the cost), which additionally involved edu-
cational materials and self-monitoring [19]. Combination
interventions address more than one cause of poor adherence,
which may explain their effectiveness compared with single-
intervention programs. For example, a single-intervention
approach of offering weekly phone calls alone by a pharmacist to
reinforce the importance of adherence [11] was not shown to be
cost-effective relative to the other interventions in this analysis.
Using a standardization procedure, the present study has
enabled a novel comparison of the efﬁcacy of disparate
adherence-improving interventions. We observed that despite
incurring higher costs, a pharmacist/nurse adherence interven-
tion program is cost-effective for improving adherence with anti-
hypertensive and lipid-lowering therapies, in comparison with
other interventions designed to improve adherence with CVD
therapies. Furthermore, the comparison showed that even within
pharmacist management approaches to improving adherence, the
design of the program can impact its overall cost-effectiveness.
For example, the additional costs of pharmacist’s time through
management in the ambulatory setting [10], where the pharma-
cist had sole responsibility for seeing the patient in a clinical
setting and following up regarding compliance, side effects and
advising about potential drug effects, did not make the interven-
tion any more cost-effective.
The pharmacist/nurse management study by Bond and
Monson, derived overall health-care cost savings through
improved medication adherence, which were reported to be more
than sufﬁcient to compensate for costs of the clinical pharma-
cist and nurse required to provide the intervention program.
Table 2 Mean (95% conﬁdence interval [CI]) simulated cardiovascular events per person for selected adherence-improving interventions
Scenario
Mean age of
death (years)
Cardiovascular event
TotalAngina Myocardial infarction Stroke
No adherence intervention* 80.7 0.135 (0.13–0.15) 0.230 (0.22–0.24) 0.210 (0.20–0.22) 0.575 (0.55–0.60)
Skaer [14] (R) 80.7 0.133 (0.13–0.14) 0.227 (0.22–0.24) 0.210 (0.20–0.22) 0.569 (0.55–0.59)
Saunders [19] (C+R) 80.7 0.133 (0.12–0.14) 0.226 (0.21–0.24) 0.208 (0.20–0.22) 0.567 (0.54–0.59)
Faulkner [11] (E) 80.7 0.133 (0.13–0.14) 0.226 (0.22–0.24) 0.208 (0.20–0.22) 0.567 (0.55–0.59)
Bond [6] (M) 80.8 0.132 (0.12–0.14) 0.222 (0.21–0.24) 0.206 (0.19–0.22) 0.560 (0.54–0.58)
Monson [10] (M) 80.8 0.130 (0.12–0.14) 0.222 (0.21–0.24) 0.206 (0.20–0.22) 0.557 (0.54–0.58)
*No adherence intervention = calcium channel blocker + statin only.
C+R, Combination + reminders; E, Education; M, Case management; R, Reminders.
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Accordingly, they considered their adherence intervention
program to be cost-effective. The data presented herein concur
with their assessment that a pharmacist and nurse adherence
reinforcement program could be cost-effective in the patient care
setting. Indeed, their 6-month retrospective analysis demon-
strated a signiﬁcant improvement in drug documentation, com-
pliance, and BP control compared with before the adherence
intervention program. Most studies identiﬁed did not correlate
health outcomes with improved adherence. Importantly, Bond
and Monson reported a signiﬁcant correlation between compli-
ance (reﬁll patterns) and adequate BP control [6], as reported by
others [18,35]. Nevertheless, when interventions, such as this
study by Bond and Monson, are assessed in isolation or versus a
control group alone, comparative analyses of cost-effectiveness
and economic viability are not feasible. Furthermore, studies are
often carried out in a variety of patient populations, therefore
complicating a direct comparison with another adherence inter-
vention from a separate study. The present study extends the
conclusion by Bond and Monson by suggesting that their phar-
macist and nurse adherence reinforcement program is cost-
effective versus other adherence-improving interventions for
CVD therapies.
The present study also conﬁrms an earlier analysis showing
that, of eligible interventions, the most effective approaches for
improving adherence, giving the highest Relative Improvement,
were the personalized, intensive interventions, involving a phar-
macist management programs [6,10] or weekly telephone coun-
seling [11]. These intensive interventions, often providing
individualized patient care, enable adherence with CVD therapies
to be closely monitored. Indeed, the higher Relative Improvement
was previously shown to be generally associated with studies
[6,7,10] that required more than one visit or contact with a
health-care professional during follow-up [20]. Adherence is a
continuous process and may change over time. Therefore, regu-
larly contacting patients and reinforcing the importance of medi-
cation and lifestyle compliance may allow health-care
professionals to provide educational and psychological support at
critical junctures. For example, adherence to antihypertensive and
lipid-lowering therapy is known to decrease over time, particu-
larly within the ﬁrst 6 months of therapy [22,29,36]. In this
manner, drug therapy and lifestyle modiﬁcations can be optimized
during regular follow-up and any patient concerns appropriately
managed. With optimized adherence with therapy on a patient-
by-patient basis, each individual will be more likely to achieve
their therapeutic goals [37–39]. But, as outlined, these interven-
tions need to be balanced and assessed against their higher costs.
A number of factors need to be considered when evaluating
the cost-effectiveness of any intervention or program designed to
improve adherence with medications. For example, overall costs
should be adjusted for a potential increase in the cost of medi-
cations because of the patient remaining more adherent with
their therapy and potentially persisting with their treatment
regimen for longer. Conversely, any reduction in overall cost of
health-care services which may occur due to a patient remaining
adherent with their medication should be accounted for. In the
case of antihypertensive and lipid-lowering agents this will be
driven by a reduction in cardiovascular events.
Using an analytic framework, we were able to adjust for the
differing levels of adherence which are seen in real-world clinical
practice [22,23]. A prior analysis demonstrated that, from a
payer’s perspective, increasing adherence to ideal levels with a
program costing up to approximately US$8400 per patient
would be as cost-effective as initiating this number of patients on
dual antihypertensive and lipid-lowering therapies at real-world
adherence, while also conferring absolute beneﬁts in life expect-Ta
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ancy and event reduction [21]. Accordingly, inﬂuencing factors
such as changes in costs and adherence levels need to be taken
into consideration when a complete cost-effectiveness assessment
is undertaken.
The present study indicates that educating the patient is a key
component of a cost-effective approach to improving adherence,
as both the pharmacist/nurse management program [6] and the
combined intervention [40] involved a large educational compo-
nent. Nevertheless, despite health-care professionals being acutely
aware of the morbidity and mortality risks associated with CVD,
especially in the presence of uncontrolled risk factors, effective
treatments are often not prescribed, or are utilized suboptimally
[5]. Thus, a different approach is needed to address CVD risk
reduction, and adherence interventions may help toward this
objective. It is important also to note that pharmacists, nurses, or
other trained health-care professionals are ideally positioned to
supervise an adherence intervention program, encouraging early
initiation and long-term maintenance of effective therapy [38,41].
The cost-effectiveness of a physician’s assistant (extender) for
dyslipidemia management has, for example, been reported versus
usual care [39]. Conversely, a nurse-led adherence intervention
program for BP control was not cost-effective versus usual care
[42]. As discussed, personalized interventions need to be offset by
higher costs and the nurse-led intervention costs, estimated to be
approximately £357.20 per patient (approx. 2007 US$712.27)
[42], were substantially higher than costs incurred in any of the
management studies identiﬁed in the present study.
This study should be interpreted in light of some limitations.
As with any literature-based analyses, these ﬁndings may be
subject to a publication bias whereby positive ﬁndings are more
likely to be published than negative ﬁndings. Nevertheless, nega-
tive studies would have been omitted during study selection, as
we were only interested in reviewing studies that documented an
adherence improvement. Observational studies have demon-
strated an association between adherence with CVD medications
above the 80% level and better therapeutic outcomes [1,2,4], and
correspondingly, an intervention would need to improve adher-
ence to have application in a patient care setting. Therefore, there
would be little need to assess cost-effectiveness for negative
studies, as an objective of this analysis was to offer prescriptive
recommendations on which adherence interventions would
confer the greatest beneﬁts in real-world use. By excluding any
studies that did not improve adherence, it is possible that cost-
effectiveness is overestimated. Studies with negative ﬁndings
might lead us to revise downward the expected beneﬁts from
similar interventions that found positive effects. Nevertheless, it
is difﬁcult to determine whether such differences in ﬁndings are
due to differences in the interventions being evaluated rather than
to a true variation across the same intervention. Although these
negative ﬁndings are valid and useful from the perspective of
providing information on aspects of interventions that may not
work, we do not think they should be included in the present
quantitative analysis.
The adherence intervention studies identiﬁed were highly het-
erogeneous with regard to study design, patient type, and com-
pliance measurement reported. Nevertheless, steps were taken to
standardize studies such that only eligible studies were included
in the cost-effectiveness model and using a standardized popula-
tion helped to remove this variable from the cost-effectiveness
analysis. The stringent inclusion criteria may have excluded other
adherence-improving interventions that were efﬁcacious but
could not be included because of their study design not comply-
ing with the criteria for this analysis. Comparison between the
relative costs and effectiveness of these interventions necessitated
calculation of standardized costs. To accomplish this, we trun-
cated all interventions to a 6-month follow-up period and, to the
extent possible, applied a common method to estimate both costs
and effects.
The assumption was made that the hypothetical ASCOT-
LLA-like population would not affect the outcome of the inter-
vention and accordingly, no adjustments were made for
differences between the patient populations included in each of
Table 4 Incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained, per cardiovascular event avoided and per life-year
gained
Total Incremental
ICER per
QALY gained
ICER per
QALY gained
Costs
(2007 US$) QALYs
Costs
(2007 US$) QALYs
ICER per QALY gained
No adherence intervention* 17,325 14.97
Skaer [14] (R) 17,505 15.00 179 0.031 5,712 dominated†
Saunders [19] (C+R) 17,520 15.01 15 0.008 1,958 4,984
Faulkner [11] (E) 17,628 15.01 109 0.006 17,229 dominated†
Bond [6] (M) 17,896 15.07 267 0.053 5,059 6,358
Monson [10] (M) 18,082 15.07 186 0.004 45,110 45,110
ICER per cardiovascular event avoided
No adherence intervention* 17,325 0.58
Skaer [14] (R) 17,505 0.57 179 -0.006 29,562 dominated†
Saunders [19] (C+R) 17,520 0.57 15 -0.003 5,695 22,406
Faulkner [11] (E) 17,628 0.57 109 0.001 dominated dominated
Bond [6] (M) 17,896 0.56 276 -0.007 54,766 54,766
Monson [10] (M) 18,082 0.56 186 -0.002 76,090 76,090
ICER per life-year gained (undiscounted years)
No adherence intervention* 17,325 21.94
Skaer [14] (R) 17,505 21.98 179 0.041 4,391 dominated†
Saunders [19] (C+R) 17,520 21.99 15 0.012 1,187 3,642
Faulkner [11] (E) 17,628 22.00 109 0.012 8,904 dominated†
Bond [6] (M) 17,896 22.07 267 0.063 4,216 4,973
Monson [10] (M) 18,082 22.06 186 -0.001 dominated dominated
*No adherence intervention = calcium channel blocker + statin only.
†Via extended dominance.
Bold type indicates interventions remaining after less effective/more costly interventions are eliminated.
C+R, Combination + reminders; E, Education; M, Case management; R, Reminders.
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the adherence-improving intervention studies identiﬁed. Using a
single hypothetical population facilitated comparison of the
adherence interventions within the model and prevented the need
to adjust for any inﬂuence of different populations, such as age or
existing comorbidities. Indeed, an independent study of the
ASCOT population has shown that the two-pill amlodipine +
atorvastatin combination is the cost-effective option over a life-
time horizon compared with amlodipine therapy alone [43], and
thus supports the use of a CCB + statin combination in an
ASCOT-LLA-like population as in the present cost-effectiveness
analysis. We used any CCB + statin as the base-case comparator,
and there is a possibility that different cardiovascular outcomes
might result when using speciﬁc CCB and/or statin products.
Nevertheless, using a general base-case comparison cohort
enabled the same “no adherence intervention” group to be used
for each intervention.
Limitations to the cost-effectiveness model have been pub-
lished previously [21], and include assumptions on adherence
rates after a cardiovascular event and the short-term interaction
of adherence and effectiveness, and extrapolations of long-term
effectiveness of antihypertensive and lipid-lowering therapy.
Assessing adherence based on measures of PDC over time may
overestimate actual drug-taking behavior because it assumes that
patients take all of the medications for prescriptions that are
ﬁlled. Additionally, in our analysis, a given day was assumed to
be covered if any drug for the indication of interest was available.
Such an approach is likely to be accurate for lipid-lowering
therapy, which generally consists of statins alone. Nevertheless,
for the treatment of hypertension, use of multiple drug regimens
is common, and we may therefore have overestimated adherence
with this method [21].
PDC has the advantage of simultaneously reﬂecting both
compliance and persistence [27,28], and is an ideal measure for
incorporation into Markov states of ﬁxed duration. Future
adherence studies should consider reporting PDC along with
other measures of adherence and persistence, to facilitate com-
parisons across interventions. Ideally, adherence studies would
include information on the distribution of medication possession
ratio (MPR) or PDC as well as proportion of patients reaching an
adherence threshold (e.g., MPR or PDC  80%). Improvements
in study methodology and reporting standards will enable more
robust comparisons of adherence interventions across studies,
which may translate into more cost-effective uses of adherence-
improving programs in clinical practice.
Past adherence research has identiﬁed a “healthy adherer”
effect, whereby patients who are observed to be more adherent,
even while taking placebo, tend to achieve better outcomes [44].
This effect has been attributed to the positive correlation between
medication adherence behaviors and other healthy lifestyle
choices. The burden of nonadherence model [21] did not adjust
for baseline patient behavior or any differences in nonmedication
adherent behaviors which could inﬂuence the likelihood of posi-
tive outcome. This is consistent with the choice of effectiveness
estimates in the model, which were informed by the efﬁcacy of
treatments as observed in randomized clinical trials versus
placebo, where adherence to active treatment and placebo was
Figure 3 Total costs versus quality adjusted life-years (QALYs) for each intervention adjusted* by partial-adherence effectiveness (PE) level. *The base-case analysis
assumed patients who were partially adherent (PDC 20–80%) received 50% of the therapeutic effectiveness that would be obtained by a fully adherent patient. In
a one-way sensitivity analysis, this assumption was varied to assume 0%, 25%, 75%, and 100% of therapeutic effectiveness for the partially adherent patients. C+R,
Combination + reminders; E, Education; M, Case management; R, Reminders.
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similar. Therefore, modeled cost-effectiveness was based purely
on the incremental efﬁcacy expected by proper use of the active
medication above no medication, and any difference in adherence
behaviors for patients who have discontinued treatment com-
pared with those who continued treatment would be a separate
effect.
Our speciﬁcation of adherence parameters may have some
inﬂuence on cost-effectiveness estimates. Categorization of
“Nonadherent” patients with PDC20% included both patients
with poor adherence and those that were totally nonadherent
(e.g., PDC of 0). Therefore, these patients with low adherence
behavior may receive some beneﬁts from taking their antihyper-
tensive and/or lipid-lowering medication and their event rate may
be overestimated as a result. Additionally, the results of this
analysis were found to be sensitive to changes in our assumptions
around partial effectiveness and the percentage of patients fully
adherent. Furthermore, the duration of therapeutic effects after
discontinuation or reduction in adherence to medication is
unknown, and patients may continue to see beneﬁts after stop-
ping therapy. The model assumed that a change in adherence
resulted in a change in event risk within 1 year, as patients were
assigned relative event risks based on current adherence status
[21]. Nevertheless, through using transition probabilities in the
model derived from ﬁlled prescription records from Medi-Cal
data [33], adherence levels for patients beyond year 1 were based
on long-term adherence patterns seen in a representative popu-
lation. Despite these limitations, combining published data with
a burden of nonadherence model has enabled a novel compara-
tive analysis of the cost-effectiveness of different interventions
that improve adherence.
Conclusion
The present study has successfully combined data describing
different adherence-improving interventions for antihypertensive
and lipid-lowering agents into a burden of nonadherence frame-
work [21]. We were therefore able to use a standardized proce-
dure to compare cost-effectiveness based on modeled costs across
interventions from a variety of studies.
Of published adherence-improving interventions, reminders
and educational materials and a pharmacist management
program appear to be the most cost-effective, and should be
considered before other types of intervention for improving
adherence with antihypertensive and lipid-lowering therapy.
Combining cost-effectiveness assessment and Relative Improve-
ment, we feel that in particular a pharmacist/nurse management
program should be considered before other types of published
intervention for improving adherence with CVD therapies. This
study provides a novel approach to assessing useful information
on the relative cost-effectiveness of adherence interventions,
which may help with both the design and successful implemen-
tation of efﬁcient adherence-improving programs.
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